Aug. 14 at 2:24 PM
$ALLO
Allogene Therapeutics, ALPHA3’s interim analysis strengthened the clinical and regulatory case for cema-cel in first-line, MRD-positive large B-cell lymphoma:
-MRD negativity at Day 45: 58.3% (7/12) cema-cel vs. 16.7% (2/12) observation.
-Absolute MRD-clearance difference: 41.6%.
-Median plasma ctDNA: -97.7% with cema-cel vs. +26.6% with observation
-No CRS, ICANS, GvHD, treatment-related serious AEs or related hospitalizations reported at the cutoff.
-FDA granted RMAT and Fast Track designations.
https://prismmarketview.com/allogenes-alpha3-data-and-fda-designations-sharpen-the-case-for-cema-cel-in-lymphoma/
#ALLO #CellTherapy #Oncology #LBCL
